Acute Lymphoblastic Leukemia (ALL) Bone Marrow Mononuclear Cells

Acute Lymphoblastic Leukemia (ALL) Bone Marrow Mononuclear Cells for Leukemia Research

Our Acute Lymphoblastic Leukemia (ALL) Bone Marrow Mononuclear Cells is a hematopoietic tissue sample isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples are sourced from IRB-consented donors clinically diagnosed with ALL, an aggressive leukemia arising from lymphoid progenitors within the marrow itself.

ALL Biology and Why Bone Marrow

• ALL arises from malignant transformation of B- or T-lymphoid progenitors within the bone marrow, where the disease originates and where diagnostic blast counts are established (typically ≥20% lymphoblasts).
• Because ALL is a marrow-based disease, bone marrow aspirate – not peripheral blood – is the reference-standard specimen for diagnosis, lineage assignment by immunophenotyping, and cytogenetic/molecular risk stratification (including Philadelphia chromosome-positive subtypes).
• Minimal residual disease (MRD) monitoring by multiparameter flow cytometry or next-generation sequencing is performed on marrow aspirate and is one of the strongest prognostic indicators in both pediatric and adult ALL.
• CD19 and CD22 are validated immunotherapy targets in B-ALL, and marrow-derived blasts are the standard substrate for CAR-T and bispecific antibody target-expression and functional studies.
• Marrow microenvironment interactions with leukemic blasts are increasingly studied for their role in chemoresistance and relapse.

Donor Stratification Available

• Lineage: B-cell versus T-cell ALL
• Cytogenetic and molecular subtype, including Philadelphia chromosome (BCR-ABL1) status
• Disease phase: newly diagnosed, post-induction, relapsed/refractory
• Blast percentage at collection where available
• Treatment history, including prior immunotherapy or stem cell transplant
• Age band and sex assigned at birth
• Matched healthy bone marrow controls available

Product Features

• Isolated from clinically confirmed ALL donor bone marrow aspirate
• Density-gradient purified and cryopreserved
• Research Use Only (RUO)
• IRB-approved protocols with documented consent
• Standard and custom cell quantities available

De-identified Donor Data

• ALL diagnosis confirmation, lineage, and cytogenetic subtype where documented
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Treatment history and disease phase where documented
• Additional ALL-specific metadata available on request

Applications

• Minimal residual disease (MRD) detection and monitoring assay development
• Blast immunophenotyping and lineage marker studies
• CAR-T and bispecific antibody target-expression and functional studies (CD19, CD22)
• Marrow microenvironment and chemoresistance research
• Cytogenetic and molecular risk-stratification studies

Other Specimen Types

For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection.

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

ALL bone marrow mononuclear cells are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations.